INIS
patients
100%
peptides
99%
heart failure
91%
mortality
59%
risks
57%
therapy
41%
morbidity
41%
brain
41%
valves
36%
stratification
36%
emergencies
36%
management
36%
concentration
27%
values
26%
nmr imaging
18%
prednisone
18%
mutations
18%
symptoms
18%
eosinophils
18%
genes
18%
tyrosine
18%
receptors
18%
growth factors
18%
fibrosis
18%
kinases
18%
hospitals
15%
sensitivity
15%
biological markers
12%
curves
10%
hazards
9%
Keyphrases
PRIMA
73%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
73%
Heart Failure
60%
Brain Natriuretic Peptide
41%
Chronic Heart Failure
41%
Guided Therapy
41%
Severe Mitral Regurgitation
36%
Risk Stratification
36%
Noncardiac
36%
Endocarditis
36%
Major Adverse Cardiovascular Events
36%
Patient Complaints
36%
Emergency Patients
36%
Heart Failure Patients
36%
Peptide Concentration
31%
Heart Failure Management
18%
Echocardiography
18%
Myocardial Fibrosis
18%
Mitral Valve Leaflets
18%
Complete Remission
18%
Mitral Valve Regurgitation
18%
Platelet-derived Growth Factor Receptor (PDGFR)
18%
Eosinophil Count
18%
Prednisone
18%
Intracardiac Mass
18%
Hypereosinophilia
18%
Intracardiac Thrombus
18%
Tyrosine Kinase Inhibitor
18%
Loeffler Endocarditis
18%
Cardiac Magnetic Resonance Imaging (cMRI)
18%
Medicine and Dentistry
Congestive Heart Failure
85%
Amino Terminal Sequence
73%
Brain Natriuretic Peptide
73%
Mitral Insufficiency
36%
Risk Stratification
36%
Eosinophilic
36%
Post-Hoc Analysis
36%
Endocarditis
36%
Acute Decompensated Heart Failure
13%
Thrombus
12%
Platelet Derived Growth Factor Alpha Receptor
12%
Hypereosinophilia
12%
Cardiac Magnetic Resonance Imaging
12%
Eosinophil
12%
Echocardiography
12%
Cardiac Fibrosis
12%
Tyrosine-Kinase Inhibitor
12%
Prednisone
12%
Mitral Valve
12%
Outpatient
6%